Location History:
- Wetter, DE (2019)
- Marburg, DE (2012 - 2022)
Company Filing History:
5 out of 3,923 
3 out of 35 
1 out of 832,891 Years Active: 2012-2022
Title: **The Innovative Contributions of Jens-Peter Gregersen**
Introduction
Jens-Peter Gregersen, an accomplished inventor based in Marburg, Germany, has significantly impacted the field of vaccine development. With a repertoire of 9 patents to his name, he focuses on enhancing the safety and efficacy of viral vaccines, ensuring that advancements in immunization translate into better public health outcomes.
Latest Patents
One of Gregersen's notable patents is for **"Cell-derived viral vaccines with low levels of residual cell DNA,"** which addresses the preparation of vaccine products aimed at preventing viral infections. This invention outlines methods for reducing contaminants in cell culture vaccines by degrading residual functional cell culture DNA with a DNA alkylating agent, such as β-propiolactone (BPL). The result is a vaccine that comprises immunogenic proteins derived from viruses grown in cell culture, which is substantially free from harmful DNA residues.
Another significant patent revolves around **"Decreasing potential iatrogenic risks associated with influenza vaccines."** Jens-Peter Gregersen identified contamination risks in conventional methods of growing influenza viruses in embryonated hen eggs and modern mammalian cell cultures. His work emphasizes the importance of performing suitable safety tests during vaccine manufacture to prevent infections that could inadvertently arise from the vaccination process.
Career Highlights
Throughout his career, Jens-Peter has worked with leading companies such as Novartis AG and Seqirus UK Limited. His contributions within these organizations have been pivotal in the development of safer and more effective vaccines. His innovative approaches to vaccine manufacturing have made a lasting impact on the industry.
Collaborations
During his professional journey, Jens-Peter Gregersen has collaborated with esteemed colleagues, including Holger Kost and Jürgen Vorlop. Their teamwork has undoubtedly played a role in advancing the scientific community's understanding of vaccine safety and efficacy.
Conclusion
Jens-Peter Gregersen exemplifies the spirit of innovation in the field of vaccine development. His 9 patents reflect a deep commitment to improving public health and reducing risks associated with viral infections. As he continues to push the boundaries of medical technology, the future of vaccine safety remains bright under his influence.